日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy

肿瘤的细菌定植会激活免疫反应并增强免疫检查点阻断的疗效。

Rolig, Annah S; Ziglari, Tahereh; McGee, Grace Helen; Kasiewicz, Melissa J; Kolbaba, Kenna; Simons, Noah D; Pucilowska, Joanna; Sfanos, Karen; Redmond, William L

The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming

抗PD-1和抗LAG-3检查点阻断疗法的疗效与调节性T细胞重编程有关。

Rolig, Annah S; Peng, Xiyu; Sturgill, Elizabeth R; Holay, Nisha; Kasiewicz, Melissa; Mick, Courtney; Mcgee, Grace Helen; Miller, William; Koguchi, Yoshinobu; Kaufmann, Johanna; Yanamandra, Niranjan; Griffin, Sue; Smothers, James; Adamow, Matthew; Lee, Jasme; Shen, Ronglai; Callahan, Margaret K; Redmond, William L

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

INBRX-106:一种六价OX40激动剂,可通过优化受体聚集驱动更强的抗肿瘤反应

Holay, Nisha; Yadav, Rashi; Ahn, Sae Jeong; Kasiewicz, Melissa J; Polovina, Anya; Rolig, Annah S; Staebler, Thi; Becklund, Bryan; Simons, Noah D; Koguchi, Yoshinobu; Eckelman, Brendan P; de Durana, Yaiza Diaz; Redmond, William L

Exosome-Mediated Cellular Communication in the Tumor Microenvironment Imparts Drug Resistance in Breast Cancer

肿瘤微环境中外泌体介导的细胞通讯赋予乳腺癌耐药性

Malla, RamaRao; Bhamidipati, Priyamvada; Samudrala, Anuveda Sree; Nuthalapati, Yerusha; Padmaraju, Vasudevaraju; Malhotra, Aditya; Rolig, Annah S; Malhotra, Sanjay V

Desmocollin-3 and Bladder Cancer

桥粒蛋白-3与膀胱癌

Shukla, Chandreshwar P; Jain, Nayan K; O'Donnell, Michael A; Vachhani, Kapil V; Patel, Rashmi; Patel, Janki; Modi, Rajiv; Dheeraj, Arpit; Lee, Jee Min; Rolig, Annah; Malhotra, Sanjay V; Khamar, Bakulesh

Diagnosis and Treatment of Laryngeal Extranodal Natural Killer/T-cell Lymphoma

喉部结外自然杀伤/T细胞淋巴瘤的诊断和治疗

Quispe-Villegas, Gustavo; Custodio, Yinno; Aliaga, Rolig

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+RT

结合 bempegaldesleukin(CD122 优先 IL-2 通路激动剂)和 NKTR-262(TLR7/8 激动剂)可提高全身抗肿瘤 CD8+ T 细胞的细胞毒性,优于 BEMPEG+RT

Annah S Rolig, Daniel C Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, William L Redmond

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor

利用半乳糖凝集素-3抑制剂贝拉普汀增强抗PD-1的临床和免疫学效应

Curti, Brendan D; Koguchi, Yoshinobu; Leidner, Rom S; Rolig, Annah S; Sturgill, Elizabeth R; Sun, Zhaoyu; Wu, Yaping; Rajamanickam, Venkatesh; Bernard, Brady; Hilgart-Martiszus, Ian; Fountain, Christopher B; Morris, George; Iwamoto, Noriko; Shimada, Takashi; Chang, ShuChing; Traber, Peter G; Zomer, Eliezer; Horton, J Rex; Shlevin, Harold; Redmond, William L

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity

贝拉普汀抑制半乳糖凝集素 3 并联合抗 OX40 疗法可重新编程肿瘤微环境,以利于抗肿瘤免疫

Elizabeth R Sturgill, Annah S Rolig, Stefanie N Linch, Courtney Mick, Melissa J Kasiewicz, Zhaoyu Sun, Peter G Traber, Harold Shlevin, William L Redmond

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8(+) T cell responses capable of curing multi-focal cancer.

NKTR-214 免疫疗法与放射疗法协同作用,刺激全身 CD8(+) T 细胞反应,从而治愈多灶性癌症

Walker Joshua M, Rolig Annah S, Charych Deborah H, Hoch Ute, Kasiewicz Melissa J, Rose Daniel C, McNamara Michael J, Hilgart-Martiszus Ian F, Redmond William L